Business Context and Reporting Period
This Form 8-K is a current report filed by Protalix Biotherapeutics, Inc. on April 7, 2011. The filing serves as a Regulation FD disclosure regarding an upcoming investor presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial condition or operations are reported in this document. The filing solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
Yossi Maimon, the Company's Chief Financial Officer, is scheduled to present at the Tel Aviv Stock Exchange 100 investment conference on Tuesday, April 12, 2011, at the Hilton Tel Aviv in Israel. The press release regarding this event is attached as Exhibit 99.1. The filing explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the date and location of the upcoming presentation: April 12, 2011, at the Hilton Tel Aviv.
- Confirm the identity of the presenter: Yossi Maimon, Chief Financial Officer.
- Note that this 8-K does not contain financial data; investors should refer to the attached press release (Exhibit 99.1) or recent 10-Q/10-K filings for financial details.